Annual General Meeting
London, UK – 22 June 2015 – NetScientific plc (“NetScientific” or “the Group”, AIM: NSCI), the biomedical and healthcare technology group, is holding its Annual General Meeting (AGM) today at 11am. Ahead of this meeting Chairman, Sir Richard Sykes, will make the following comments:
“2015 has been transformational for the Group’s evolution. Notably, our Board review of the business strategy has led to a revitalised focus on funding, development and management of early and mid-stage healthcare technology companies, sourced from USA and UK strategic partnerships. We are concentrating on three core areas – proven technology in digital health, diagnostics and therapeutics. These sectors represent highly attractive growth markets where breakthrough technology solutions are in high demand.
“The appointment of François Martelet as CEO in June was well timed for him to lead on the new strategy, bringing over 20 years’ of biopharma experience and knowledge of commercialisation with him to further strengthen the team. François will be presenting at the AGM to highlight his next steps in the management of the Group including his plans to undergo an in-depth, systematic portfolio review in the three healthcare segments. He will stress his intention to accelerate growth in NetScientific’s lead portfolio companies – Wanda, Vortex, Glucosense, Glycotest and Proaxsis and divest interests in non-core assets. A fuller update will follow with the interim results in September.
“Today Nicholas Heckford, Executive Director – Commercial and Legal, has announced his retirement and departure from the Board at the end of September. Most of his responsibilities will be taken up by the Company Secretary, Ernest Schneider. Nicholas has been with the Group since inception and his contribution has been significant and much appreciated. We wish him all the best in his retirement.”
François Martelet’s presentation will be available on Netscientific’s website after the meeting.
NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people’s lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.netscientific.net
Peter Thoms, CFO
Tel: +44 (0)77 2055 5752
Gary Clarence / Daniel Adams
Tel: +44 (0)20 7597 4000
Melanie Toyne-Sewell / Jayne Crook
Tel: +44 (0)20 7457 2020 Email: firstname.lastname@example.org